Jane Robertson

Jane is Chief Medical Officer at Redx Pharma, a clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancers and fibrotic diseases, where she leads the clinical development strategy and delivery.. Since she joined Redx in March 2021, Redx has progressed its lead oncology candidate into Phase 2 clinical trials in pancreatic cancer, colorectal cancer and biliary tract cancers, and its lead fibrosis candidate into clinical development in IPF.

Prior to Redx, Jane was Chief Medical Officer at Achilles Therapeutics Ltd, a biotech company focused on the creation of personalized T cell therapies directed against clonal tumour neoantigens. During her 3-year tenure at Achilles, the Company progressed its two cell therapy products into clinical trials in melanoma and non-small cell lung cancer. Before joining Achilles, Jane served as the Chief Medical Officer at Nucana Biomed Ltd and at Kesios Therapeutics Ltd, both oncology biotech companies. She previously held several senior R&D leadership roles at AstraZeneca Oncology, notably leading the development and first regulatory approval of the first-in-class PARP inhibitor, Olaparib (Lynparza) in 2014.

Jane qualified in medicine from the universities of Oxford and London and trained in general medicine and haematology, working in clinical practice and translational research settings, gaining her MD, MRCP and FRCPath, and specialising in haemato-oncology. She is General Medical Council registered, an affiliate member of the Faculty of Pharmaceutical Medicine and an Honorary Consultant Haematologist at the Christie Hospital, Manchester, UK.